Monoclonal antibody drug conjugates in the treatment of cancer

Current Opinion in Immunology

Volumn 11, Issue 5, 1999, Pages 584-588

  Trail, Pamela A ^a   Bianchi, Albert B ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CALICHEAMICIN; DOXORUBICIN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; CANCER; CANCER IMMUNOTHERAPY; CARCINOMA; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; DRUG ACTIVITY; DRUG CONJUGATION; DRUG POTENCY; DRUG TARGETING; DRUG TOXICITY; FEVER; GASTRITIS; GASTROINTESTINAL TOXICITY; HUMAN; NAUSEA; PHASE 1 CLINICAL TRIAL; REVIEW; VOMITING;

EID: 0032872567     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00012-6     Document Type: Review

References (43)

1. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead SJ, Casazza AM, Firestone RA, Hellström I, Hellström KE Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 261:1993;212-215.
2. Sjögren HO, Isaksson M, Willner D, Hellström I, Hellström KE, Trail PA Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res. 57:1997;4530-4536.
3. 2antigen was used to evaluate immunoconjugate activity.
4. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter Bet al. Radiolabeled-antibody therapy of B cell lymphoma with autologous bone marrow support. N Engl J Med. 329:1993;1219-1224.
5. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 93:1999;3678-3684. This paper reports a phase I trial of an anti-CD33-calicheamicin conjugate, CMA-676, demonstrating a 20% response rate in patients with refractory AML. The study design included evaluation of the levels of saturation of CD33 sites and addressed the impact of a multi-drug-resistance phenotype on clinical response.
6. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche Het al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 16:1998;1788-1794. This study of 189 patients shows that 17-1A antibody, when used to treat minimal residual disease (post resection of Dukes' C colon carcinoma), prevented the development of distant metastasis in approximately one third of patients. The therapeutic effect was maintained after seven years of follow-up evaluation.
7. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga MM, Tripathy D, Baly D, Baighman SA, Twaddell T, Glaspy JA, Slalom DJ Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 16:1998;2659-2663.
8. Jain RK Delivery of molecular and cellular medicine to solid tumors. J Control Release. 53:1998;49-67. This reviews the physical barriers of solid tumors that impair the penetration, distribution and efficacy of MAb-directed therapies.
9. Saleh MN, LoBuglio AF, Trail PA Immunoconjugate therapy of solid tumors: studies with BR96-doxorubicin. Grossbard M Monoclonal Antibody-Based Therapy of Cancer. 1998;397-416 Marcel Dekker, New York. This chapter discusses the preclinical biology and Phase I findings of BR96-DOX, an anticarcinoma immunoconjugate. Data from the Phase I trial demonstrate BR96-directed delivery of DOX in patient tumor biopsies and evidence of biologic activity. Low response rates indicate the need for further optimization for the conjugate to be clinically acceptable. It is suggested that BR96-DOX, like other MAb therapies, will be most effective when evaluated in minimal-disease settings.
10. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 53:1993;3336-3342.
11. King HD, Yurgaitis D, Willner D, Firestone RA, Yang MB, Lasch SJ, Hellstrom KE, Trail PA Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates. Bioconjug Chem. 10:1999;279-288. The authors describe a novel conjugation strategy to increase immunoconjugate potency by increasing the amount of drug delivered per MAb. These linkers attach two DOX molecules per thiol to the MAb and the conjugates demonstrate potent antigen-specific cytotoxicity in vitro.
12. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 118:1997;153-160.
13. Lopes de Menezes DE, Pilarski LM, Allen TM In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58:1998;3320-3330. A study demonstrating the potential to use internalizing MAbs to deliver sterically stabilized DOX immunoliposomes in minimal-disease lymphoma models.
14. Tseng YL, Hong RL, Tao MH, Chang FH Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer. 80:1999;723-730.
15. Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein AL Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res. 5:1999;51-60.
16. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.
17. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. 58:1998;4646-4653. This paper describes a strategy to inhibit tumor growth by selectively forming thrombi in the tumor vasculature. A MAb to a naturally occurring endothelial marker, vascular cell adhesion molecule 1 (VCAM-1), was used to target the extracellular domain of tissue factor.
18. Arap W, Pasqualini R, Ruoslahti E Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380. These studies use in vivo selection of phage display libraries to identify peptides that selectively localize in tumor blood vessels. This is an interesting approach to identify novel cell surface markers with selectivity for the tumor vasculature.
19. Arap W, Pasqualini R, Ruoslahti E Chemotherapy targeted to tumor vasculature. Curr Opin Oncol. 10:1998;560-565.
20. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res. 5:1999;371-382.
21. Smith AL, Nicolaou KC The enediyne antibiotics. J Med Chem. 39:1996;2103-2117.
22. Kondo S, Nakatsu S, Sakahara H, Kobayashi H, Konishi J, Namba Y Antitumour activity of an immunoconjugate composed of anti-human astrocytoma monoclonal antibody and neocarzinostatin. Eur J Cancer. 3:1993;420-423.
23. Okamoto K, Yamaguchi T, Otsuji E, Yamaoka N, Yata Y, Tsuruta H, Kitamura K, Takahashi T Targeted chemotherapy in mice with peritoneally disseminated gastric cancer using monoclonal antibody-drug conjugate. Cancer Lett. 122:1998;231-236.
24. Otsuji E, Yamaguchi T, Tsuruta H, Yata Y, Nishi H, Okamoto K, Taniguchi K, Kato M, Kotani T, Kitamura Ket al. The effect of intravenous and intra-tumoural chemotherapy using a monoclonal antibody-drug conjugate in a xenograft model of pancreatic cancer. Eur J Surg Oncol. 21:1995;61-65.
25. Schmidt CS, Wrasidlo W, Kaufmann O, Scherberich JE, Gaedicke G, Fischer P Monoclonal antibody 138H11 against gamma-glutamyltransferase provides a possible tool for targeting calicheamicin theta to renal cell carcinomas. Adv Exp Med Biol. 451:1998;431-436.
26. Siegel MM, Tabei K, Kunz A, Hollander IJ, Hamann RR, Bell DH, Berkenkamp S, Hillenkamp F Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Anal Chem. 69:1997;2716-2726.
27. Trail PA, Willner D, Hellstrom KE Site-directed delivery of anthracyclines for cancer therapy. Drug Dev Res. 34:1995;196-209.
28. Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR, Greenfield RS, Kaneko T, Firestone RA (6-maleimidocaproyl)- hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjugate Chem. 4:1993;521-527.
29. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 17:1999;478-484. This article describes a Phase II clinical study of BR96-DOX in patients with metastatic breast cancer.
30. y- related cell surface antigen. Cancer Res. 50:1990;2183-2190.
31. Hellström I, Hellström KE, Siegall CB, Trail PA: Immunoconjugates and immunotoxins for therapy of carcinomas. In Advances in Pharmacology, vol 33, edn 1. Edited by August JT, Anders MW, Murad F, Coyle JT. San Diego: Academic Press; 1995:349-388.
32. Stan AC, Radu DL, Casares S, Bona CA, Brumeanu TD Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Cancer Res. 59:1999;115-121.
33. Shih LB, Goldenberg DM, Xuan H, Lu H, Sharkey RM, Hall TC Anthracycline immunoconjugates prepared by a site specific linkage via an amino-dextran intermediate carrier. Cancer Res. 51:1991;4192-4198.
34. Omelyanenko V, Gentry C, Kopeckova P, Kopecek J HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer. 75:1998;600-608.
35. Crosasso P, Brusa P, Dosio F, Arpicco S, Pacchioni D, Schuber F, Cattel L Antitumoral activity of liposomes and immunoliposomes containing 5- fluorouridine prodrugs. J Pharm Sci. 86:1997;832-839.
36. Allen TM, Hansen C Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1068:1991;133-141.
37. Huwyler J, Yang J, Pardridge WM Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J Pharmacol Exp Ther. 282:1997;1541-1546.
38. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta. 1239:1995;133-144.
39. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 36:1997;66-75.
40. Folkman J New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 14:1996;2534-2539.
41. Olson TA, Mohanraj D, Roy S, Ramakrishnan S Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer. 73:1997;865-870.
42. Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res. 59:1999;183-188.
43. Brekken RA, Huang X, King SW, Thorpe PE Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 58:1998;1952-1959.